“…[3][4][5] In contrast to visceral ESTs, which often prove fatal within a short time, patients with orbital ESTs may survive longer as the result of earlier recognition and prompt treatment. 3,5 Serum ␣-fetoprotein, a useful marker in the diagnosis and follow-up of gonadal ESTs, also has been found to be increased in patients with orbital ESTs. 5,9,10 In our patient, serum ␣-fetoprotein levels decrease to within normal range 6 weeks after the institution of chemotherapy.…”